Arcturus Therapeutics Holdings Inc. Quarterly Net Income (Loss) Attributable to Parent in USD from Q2 2018 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Arcturus Therapeutics Holdings Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q2 2018 to Q3 2024.
  • Arcturus Therapeutics Holdings Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was -$6.9M, a 57.4% increase year-over-year.
  • Arcturus Therapeutics Holdings Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was -$62.6M, a 163% decline year-over-year.
  • Arcturus Therapeutics Holdings Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$29.7M, a 418% decline from 2022.
  • Arcturus Therapeutics Holdings Inc. annual Net Income (Loss) Attributable to Parent for 2022 was $9.35M.
  • Arcturus Therapeutics Holdings Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$204M, a 182% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$62.6M -$6.9M +$9.32M +57.4% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-07
Q2 2024 -$72M -$17.2M +$35.3M +67.2% Apr 1, 2024 Jun 30, 2024 10-Q 2024-11-07
Q1 2024 -$107M -$26.8M -$77.6M -153% Jan 1, 2024 Mar 31, 2024 10-Q 2024-11-07
Q4 2023 -$29.7M -$11.7M -$129M -110% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-14
Q3 2023 $99.3M -$16.2M +$19M +54% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-07
Q2 2023 $80.3M -$52.6M -$31M -144% Apr 1, 2023 Jun 30, 2023 10-Q 2024-11-07
Q1 2023 $111M $50.8M +$102M Jan 1, 2023 Mar 31, 2023 10-Q 2024-11-07
Q4 2022 $9.35M $117M +$156M Oct 1, 2022 Dec 31, 2022 10-K 2024-03-14
Q3 2022 -$147M -$35.3M +$18.8M +34.8% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-14
Q2 2022 -$165M -$21.6M +$33M +60.5% Apr 1, 2022 Jun 30, 2022 10-Q 2023-11-14
Q1 2022 -$198M -$51.2M +$5.18M +9.19% Jan 1, 2022 Mar 31, 2022 10-Q 2023-11-14
Q4 2021 -$204M -$38.7M -$7.56M -24.3% Oct 1, 2021 Dec 31, 2021 10-K 2022-03-01
Q3 2021 -$196M -$54.1M -$33.1M -157% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-09
Q2 2021 -$163M -$54.6M -$44.3M -432% Apr 1, 2021 Jun 30, 2021 10-Q 2022-11-09
Q1 2021 -$119M -$56.3M -$46.6M -476% Jan 1, 2021 Mar 31, 2021 10-Q 2022-11-09
Q4 2020 -$72.1M -$31.1M -$20.1M -183% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-01
Q3 2020 -$52M -$21M -$13.6M -183% Jul 1, 2020 Sep 30, 2020 10-K 2022-03-01
Q2 2020 -$38.5M -$10.3M -$9.58M -1398% Apr 1, 2020 Jun 30, 2020 10-K 2022-03-01
Q1 2020 -$28.9M -$9.78M -$2.89M -42% Jan 1, 2020 Mar 31, 2020 10-K 2022-03-01
Q4 2019 -$26M -$11M Oct 1, 2019 Dec 31, 2019 10-K 2021-03-01
Q3 2019 -$7.43M -$3.18M -74.8% Jul 1, 2019 Sep 30, 2019 10-K 2021-03-01
Q2 2019 -$685K +$9.27M +93.1% Apr 1, 2019 Jun 30, 2019 10-K 2021-03-01
Q1 2019 -$6.88M Jan 1, 2019 Mar 31, 2019 10-K 2021-03-01
Q3 2018 -$4.25M Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-08
Q2 2018 -$9.95M Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-14
* An asterisk sign (*) next to the value indicates that the value is likely invalid.